Important disclosures. This website contains forward-looking statements regarding AlfredAI's products, regulatory plans, and CMS reimbursement opportunities. AlfredAI is not FDA cleared; the SaMD pre-submission is targeted for Q4 2026. Clinical evidence referenced is preliminary and not intended as proof of safety or efficacy. CMS billing figures represent addressable opportunity, not guaranteed revenue. Nothing on this site constitutes an offer or solicitation to sell securities, medical advice, or a substitute for professional clinical judgment. All trademarks are the property of their respective owners.
© 2026 AlfredAI, Inc. All rights reserved.